FDA green and red lights: Q1 2024
A roundup of the first quarter's key oncology drug approvals and rejections.
ASCO-GU – picking apart Exelixis’s Contact-02 win
A rare success for Cabometyx sees a survival benefit, but the control regimen raises questions.
ASH 2023 – a new EZ battle shapes up
Daiichi aims to expand valemetostat into a new use, but Haihe Biopharma isn't far behind.
